{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:42:21Z","timestamp":1791805341201,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chemotherapy-induced amenorrhea (CIA) is one of the most frequent therapy-related adverse events observed in breast cancer patients who have undergone chemotherapy. Although the characteristics of CIA have been studied in Western countries, little is known about CIA in Asian. We conducted a retrospective analysis to assess the characteristics and influencing factors of CIA and its association with menopause in Chinese women who underwent adjuvant chemotherapy for early-stage breast cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seventy-three premenopausal women who underwent adjuvant chemotherapy for early stage (stages I to III) breast cancer were analyzed. Patient clinical characteristics, treatment regimes, menstrual information, and serum hormone values were collected retrospectively. Characteristic factors relevant to the onset of CIA and menopause were also estimated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Approximately 83.6% of patients developed CIA. Older patients (&gt;40 years old) had higher CIA incidence compared with younger patients (<jats:italic>P<\/jats:italic> &lt;0.0001). The onset of menopause was correlated with age (<jats:italic>P<\/jats:italic> &lt;0.0001) and tamoxifen use (<jats:italic>P<\/jats:italic> = 0.0313). On the basis of the Kaplan\u2013Meier analysis, a significant difference was observed in the time of onset of permanent amenorrhea as determined by menstrual history and hormone levels (<jats:italic>P<\/jats:italic> = 0.0028). In women aged 46 to 49 years, the beginning of permanent amenorrhea was detected earlier via the clinical method than via the hormonal method (2 months versus 23 months, <jats:italic>P<\/jats:italic> &lt;0.0001). In the analysis of patients \u226550 years old, the median time to detection of permanent amenorrhea was 19 months in the hormonal test and 2 months in the clinical test (<jats:italic>P<\/jats:italic> = 0.0112).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Age at diagnosis is a predictor of the onset of amenorrhea and transformation into menopause among premenopausal breast cancer patients. Adjuvant tamoxifen therapy substantially affects the onset of menopause. A delay of the onset of serum hormone postmenopausal status was observed compared with clinical symptoms. This interval was approximately 21 months in patients aged 46 to 49 years and 17 months in patients aged over 50 years. This interval is significant in the clinical estimate of the menstrual status.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7819-11-101","type":"journal-article","created":{"date-parts":[[2013,5,20]],"date-time":"2013-05-20T17:31:42Z","timestamp":1369071102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels"],"prefix":"10.1186","volume":"11","author":[{"given":"Kexin","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,20]]},"reference":[{"key":"1311_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu JQ, Ward E: Cancer statistics 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322\/caac.20073.","journal-title":"CA Cancer J Clin"},{"key":"1311_CR2","volume-title":"SEER Cancer Statistics Review","author":"MJ Horner","year":"1975","unstructured":"Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK: SEER Cancer Statistics Review. 1975, Bethesda, MD: National Cancer Institute, [http:\/\/seer.cancer.gov\/csr\/1975_2006\/], \u20132006 []"},{"key":"1311_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-008-0303-z","volume":"117","author":"L Fan","year":"2009","unstructured":"Fan L, Zheng Y, Yu K-D, Liu G-Y, Wu J, Lu J-S, Shen K-W, Shen Z-Z, Shao Z-M: Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat. 2009, 117: 409-416. 10.1007\/s10549-008-0303-z.","journal-title":"Breast Cancer Res Treat"},{"key":"1311_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005, 365: 1687-1717.","journal-title":"Lancet"},{"key":"1311_CR5","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1200\/JCO.2004.01.159","volume":"22","author":"AH Partridge","year":"2004","unstructured":"Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszn M, Rein A, Winer EP: Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004, 22: 4174-4222. 10.1200\/JCO.2004.01.159.","journal-title":"J Clin Oncol"},{"key":"1311_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10549-009-0426-x","volume":"120","author":"JA Perez-Fidalgo","year":"2010","unstructured":"Perez-Fidalgo JA, Rosello S, Garcia-Garre E, Jorda E, Martin-Martorell P, Bermejo B, Chirivella I, Guzman C, Lluch A: Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat. 2010, 120: 245-251. 10.1007\/s10549-009-0426-x.","journal-title":"Breast Cancer Res Treat"},{"key":"1311_CR7","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/annonc\/mdh266","volume":"15","author":"S Di Cosimo","year":"2004","unstructured":"Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandala M, Milella M, Ruggeri EM, Cognetti F: Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol. 2004, 15: 1065-1071. 10.1093\/annonc\/mdh266.","journal-title":"Ann Oncol"},{"key":"1311_CR8","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996, 14: 1718-1729.","journal-title":"J Clin Oncol"},{"key":"1311_CR9","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1200\/JCO.2005.03.3969","volume":"24","author":"JA Petrek","year":"2006","unstructured":"Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006, 24: 1045-1051. 10.1200\/JCO.2005.03.3969.","journal-title":"J Clin Oncol"},{"key":"1311_CR10","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1016\/j.ejca.2009.09.019","volume":"45","author":"M Rosendahl","year":"2009","unstructured":"Rosendahl M, Ahlgren J, Andersen J, Bergh J, Blomquist C, Lidbrink E, Lindman H, Mouridsen H, Bjerre K, Andersson M: The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000\u20131 study. Eur J Cancer. 2009, 45: 3198-3204. 10.1016\/j.ejca.2009.09.019.","journal-title":"Eur J Cancer"},{"key":"1311_CR11","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1200\/JCO.2005.07.096","volume":"23","author":"WR Parulekar","year":"2005","unstructured":"Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI: Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA5. J Clin Oncol. 2005, 23: 6002-6008. 10.1200\/JCO.2005.07.096.","journal-title":"J Clin Oncol"},{"key":"1311_CR12","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.fertnstert.2007.09.048","volume":"90","author":"A Reh","year":"2008","unstructured":"Reh A, Oktem O, Oktay K: Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008, 90: 1635-1639. 10.1016\/j.fertnstert.2007.09.048.","journal-title":"Fertil Steril"},{"key":"1311_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10549-008-0071-9","volume":"115","author":"HS Han","year":"2009","unstructured":"Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, Lee H, Lee ES, Kang H, Kim SW: Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009, 115: 335-342. 10.1007\/s10549-008-0071-9.","journal-title":"Breast Cancer Res Treat"},{"key":"1311_CR14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/oxfordjournals.annonc.a057718","volume":"1","author":"A Goldhirsch","year":"1990","unstructured":"Goldhirsch A, Gelber RD, Castiglione M: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990, 1: 183-188.","journal-title":"Ann Oncol"},{"key":"1311_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10549-008-9937-0","volume":"113","author":"SM Swain","year":"2009","unstructured":"Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA: Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009, 113: 315-320. 10.1007\/s10549-008-9937-0.","journal-title":"Breast Cancer Res Treat"},{"key":"1311_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/gme.0b013e3181844877","volume":"16","author":"S Lee","year":"2009","unstructured":"Lee S, Kil WJ, Chun M, Jung YS, Kang SY, Kang SH, Oh YT: Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause. 2009, 16: 98-103. 10.1097\/gme.0b013e3181844877.","journal-title":"Menopause"},{"key":"1311_CR17","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1200\/JCO.2005.03.0783","volume":"24","author":"International Breast Cancer Study Group","year":"2006","unstructured":"International Breast Cancer Study Group: Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph-node positive breast cancer: international breast cancer study group trial 13\u201393. J Clin Oncol. 2006, 24: 1332-1341.","journal-title":"J Clin Oncol"},{"key":"1311_CR18","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1200\/JCO.2006.07.2793","volume":"24","author":"JM Walshe","year":"2006","unstructured":"Walshe JM, Denduluri N, Swain SM: Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006, 24: 5769-5779. 10.1200\/JCO.2006.07.2793.","journal-title":"J Clin Oncol"},{"key":"1311_CR19","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.1999.17.8.2365","volume":"17","author":"PJ Goodwin","year":"1999","unstructured":"Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N: Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999, 17: 2365-2370.","journal-title":"J Clin Oncol"},{"key":"1311_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/01.coc.0000251398.57630.4f","volume":"30","author":"YL Tham","year":"2007","unstructured":"Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R: The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007, 30: 126-132. 10.1097\/01.coc.0000251398.57630.4f.","journal-title":"Am J Clin Oncol"},{"key":"1311_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/CAD.0b013e3283243df3","volume":"20","author":"AM Minisini","year":"2009","unstructured":"Minisini AM, Menis J, Valent F, Andreetta C, Alessi B, Pascoletti G, Piga A, Fasola G, Puglisi F: Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era. Anticancer Drugs. 2009, 20: 503-507. 10.1097\/CAD.0b013e3283243df3.","journal-title":"Anticancer Drugs"},{"key":"1311_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cncr.24835","volume":"116","author":"ME Abusief","year":"2010","unstructured":"Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH: The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010, 116: 791-798. 10.1002\/cncr.24835.","journal-title":"Cancer"},{"key":"1311_CR23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/030089168607200108","volume":"72","author":"G Delrio","year":"1986","unstructured":"Delrio G, Deplacido S, Pagliarulo C, Distria M, Fasano S, Marinelli A, Citarella F, Desio L, Contegiacomo A, Iaffaioli RV, Petrella G, Ricciardi I, Bianco AR: Hypothalamic\u2013pituitary\u2013ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori. 1986, 72: 53-61.","journal-title":"Tumori"},{"key":"1311_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1477-7819-7-88","volume":"7","author":"T Nagao","year":"2009","unstructured":"Nagao T, Kira M, Takahashi M, Honda J, Hirose T, Tangoku A, Zembutsu H, Nakamura Y, Sasa M: Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration. World J Surg Oncol. 2009, 7: 88-10.1186\/1477-7819-7-88.","journal-title":"World J Surg Oncol"},{"key":"1311_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/humupd\/dmh052","volume":"11","author":"K Lutchman Singh","year":"2005","unstructured":"Lutchman Singh K, Davies M, Chatterjee R: Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update. 2005, 11: 69-89.","journal-title":"Hum Reprod Update"},{"key":"1311_CR26","volume-title":"Technical Report Series: Research on the Menopause","author":"World Health Organization","year":"1981","unstructured":"World Health Organization: Technical Report Series: Research on the Menopause. 1981, Geneva, Switzerland: WHO Technical Report Series No. 670"},{"key":"1311_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ctrv.2010.05.005","volume":"37","author":"O Ortmann","year":"2011","unstructured":"Ortmann O, Pagani O, Jones A, Maass N, Noss D, Rugo H, van de Velde C, Aapro M, Coleman R: Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treat Rev. 2011, 37: 97-104. 10.1016\/j.ctrv.2010.05.005.","journal-title":"Cancer Treat Rev"},{"key":"1311_CR28","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","volume":"24","author":"IE Smith","year":"2006","unstructured":"Smith IE, Dowsett M, Yap YS, Walsh G, L\u00f8nning PE, Santen RJ, Hayes D: Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006, 24: 2444-2447. 10.1200\/JCO.2005.05.3694.","journal-title":"J Clin Oncol"},{"key":"1311_CR29","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1093\/humrep\/del201","volume":"21","author":"RA Anderson","year":"2006","unstructured":"Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA: The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006, 21: 2583-2592. 10.1093\/humrep\/del201.","journal-title":"Hum Reprod"},{"key":"1311_CR30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.24746","volume":"116","author":"HI Su","year":"2010","unstructured":"Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, Freeman EW, Gracia CR, DeMichele A: Anti-mullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010, 116: 592-599. 10.1002\/cncr.24746.","journal-title":"Cancer"},{"key":"1311_CR31","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1210\/jc.2003-030352","volume":"88","author":"EC Larsen","year":"2003","unstructured":"Larsen EC, M\u00fcller J, Schmiegelow K, Rechnitzer C, Andersen AN: Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab. 2003, 88: 5307-5314. 10.1210\/jc.2003-030352.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-11-101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:54:58Z","timestamp":1630540498000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-11-101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,20]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1311"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-11-101","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,20]]},"assertion":[{"value":"21 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"101"}}